FDA Approves Apalutamide for Some Men with Prostate Cancer

In the trial that led to the approval, apalutamide (Erleada) delayed cancer metastasis for men with prostate cancer that is resistant to androgen deprivation therapy.

Cancer Currents: An NCI Cancer Research Blog